Abstract

DEVELOPMENT AND EVALUATION OF MUCOADHESIVE NANOPARTICLES A NOVEL DRUG DELIVERY FOR THE MANAGEMENT OF PARKINSONISM DISEASES

Jisha Gopi and Umesh Kumar Sharma*

Abstract

Anti Parkinson's drugs are used for the management of a neurodegenerative disorder characterized by a multifactorial nature because of reduction in dopamine level in the human brain called Parkinsonism. Normally a combination of two drugs namely Levodopa and Carbidopa is used in a ratio of 4:1 for the management of parkinsonism. Subsequently, strict adherence to the dosing frequency is strongly emphasised to attain therapeutic effects of the drug, in this research the efforts have been taken to develop a mucoadhesive drug delivery systems using nanoparticle technology. Nanoparticles were prepared by spray drying techniques. The drugs [Levodopa and Carbidopa (4:1)] was fused into the nanoparticles, the percentage yield, loading efficiency, surface characteristic studies, particle size, swelling index, drug content, ex vivo, drug release, drug distribution were carried out. Results: The yield percentage and drug loading were determined as 98.5 ± 0.5% and 84.06 ± 0.5%, respectively. The microphotographs revealed that the nanoparticles possess smooth surface and were spherical in shape, with particle size about 460 nm with 390 - 540 range of scattering and swelling Index was found to be 185.6±12%. The mucoadhesive strength was revealed to excellent (9.08± 05 hr) during ex vivo studies. The release of drug was prolonged to about 12 hr from the developed formulation. The prolonged retention in GIT (~12 h) also proves the benefits associated with oral delivery of nanoparticles with higher efficiency. Conclusion: The developed formulation of mucoadhesive nanoparticles may possibly help as the perfect technology for the effective and safe administration of anti- parkinsonism drugs for the management of Parkinsonism disease.

Keywords: Parkinsonism, Levodopa, Carbidopa, Nanoparticle, Mucoadhesive, Spray drying, Burst release.